CHARISSE MAGSAYSAY: Open Payments
NPI 1568061117 · TUSTIN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,195 in 164 payments from 49 companies in 2025. Trend: 2023 $1,352 · 2024 $5,448 · 2025 $4,195
Food & beverage: $3,561Education: $535Long term medical supply or device loan: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 21 | $435 |
| AstraZeneca Pharmaceuticals LP | 9 | $350 |
| SOBI, INC | 6 | $300 |
| Janssen Biotech, Inc. | 12 | $269 |
| Astellas Pharma US Inc | 5 | $221 |
| Celgene Corporation | 12 | $209 |
| Gilead Sciences, Inc. | 4 | $202 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $180 |
| Eisai Inc. | 6 | $134 |
| PFIZER INC. | 7 | $134 |
Products named: KISQALI, Nubeqa, ERLEADA, Lenvima, REBLOZYL, Epclusa, IMFINZI, BRAFTOVI.
Industry payments across CA — which companies pay providers there.
